The new Pfizer partnership with Flagship will fund the development of up to 10 drug

A new analysis finds that 40% of Medicare beneficiaries living with Parkinson's did not

The battle to provide obesity treatments jumps to a new level, with Eli Lilly announcing

By going down to the molecular level, doctors have uncovered a way to treat tumors

CMS should be increasing — not decreasing — access to the nutritious food people need.

Bad news: You have to get bitten a lot to acquire this superpower. At least

Almost half of U.S. adults would be willing to spend up to $100 a month

AstraZeneca has been trying to ratchet up its rare disease efforts, spending $39 billion in

Johnson & Johnson expanded global access to tuberculosis drug this week amid novelist and YouTube star

Because they slow down digestion in early weeks, drugs like Ozempic and Mounjaro have implications

Too much emphasis on the risks of gain-of-function may hold back important research

Researchers turn to CRISPR to unlock one of the trickiest diseases to treat: Alzheimer's

Lilly shows off data that suggests it could soon have a potent new injectable and

Five elderly people have been blinded by a severe side effect after receiving injections of

Scientists worry the recent controversy over human embryo models could lead to regulatory backlash and

Wegovy and similar drugs weren't originally designed to get into the brain. But scientists

A rise in cancer rates among younger people is worrying and puzzling doctors.

Scientists report they found that 32 proteins may be key to the early onset of

The case turned on claims that a deal Gilead and Teva reached to end patent

A pill under development by Lilly could offer weight loss benefits in parts of the

“If this vaccine could reduce the disease by 50%, that has tremendous implications worldwide.”

Biogen shareholders voted to add biotech executive Susan Langer, who is the romantic partner of

Nonalcoholic fatty liver disease is estimated to affect about 24% of U.S. adults. New data

Roche’s announcement that it would pay $310 million for rights to a hypertension treatment

A drug developed by the biotech firm BridgeBio to treat an increasingly common heart condition

A central promise of our modern biomedical system — that if academics make lifesaving discoveries, industry

The American Diabetes Association said Sunday that all adults with type 2 diabetes or prediabetes

A U.K. government agency said that it won’t recommend Eli Lilly’s Mounjaro for

Argenx's antibody treatment, Vyvgart, significantly delayed the progression of an autoimmune nerve disorder called

Patient advocates are warning that a proposal from the FDA meant to reduce consumers’ salt

The strongest identified single genetic risk factor for schizophrenia turns out to be linked to

A combination of strict eligibility criteria and special requirements for insurance coverage mean that less

SARS-CoV-2 has not yet fallen into a predictable seasonal pattern of the type

Recent alarmism around leprosy in Florida highlights the need for additional education on the disease

Over the weekend, Intellia sought to address concerns in the gene editing community about accidental

“We estimated that there were approximately 10 million people in the first year of the

Apellis Pharmaceuticals said it had identified a possible cause of severe eye inflammation reported in

The CDC said it’s too early to tell whether a new version of the

I tried an untested a DIY therapy, and it worked.

Astellas was so sure that one of its drugs was going to be selected as

A new study says that most cancer screening doesn’t save lives. But proving that

Swiss drugmaker Novartis’ research and development hub has a new name — and a new guiding

Brian Wallach, ALS advocate: “We know that these treatments are not cures, but they are

Crinetics Pharmaceuticals announced its experimental drug for acromegaly succeeded in a Phase 3 trial.

While the angst over another rise in Covid cases is understandable, there’s something we

Reporting from the frontiers of health and medicine

Some two years after splitting biotech company Bluebird Bio into two entities, the spinout focused

With better data, powerful genomic tools, and a rich cultural awareness of the communities they

“It’s like a light wind blowing in favor of patisiran over placebo,” said David

Eli Lilly disclosed results showing an experimental drug that targets three hormones led to 24.2